Ranibizumab for
Edema of the mAcula in
Diabetes:
Protocol 3 with High Dose -
the
READ
3
Study
The goal of the READ-3 Study, a large multi-center clinical trial
conducted across the United States, is to investigate the safety,
tolerability, and bioactivity of two different doses (0.5mg and
2.0mg) of ranibizumab, a monoclonal antibody against VEGF, in eyes
with diabetic macular edema.
The READ-3 Study is sponsored by the Juvenile Diabetes Research
Foundation. The study
drug, ranibizumab, is provided by Genentech, Inc.